The COVID-19 mRNA vaccines (Pfizer/BioNTech and Moderna), according to three studies issued by the CDC in August 2021, are becoming less effective with time. The trials, which were all published in MMWR, reveal that after the second dose, vaccine protection against mild to moderate infection begins to wane. Vaccines, on the other hand, continue to offer excellent protection against serious illness, hospitalization, and death.
It's possible that the rise in mild and moderate breakthrough infections isn't entirely related to a reduction in vaccination protection. It's possible that the immunizations aren't as successful as they were against previous versions against the Delta form. In addition, safety procedures like mask use and physical separation have declined in recent months. All of these factors could contribute to an increase in outbreak illnesses among those who have been fully vaccinated.
The effectiveness of the Johnson & Johnson vaccination over time was not addressed in the MMWR investigations.
My immune system is compromised. Is a third dosage of the COVID-19 vaccination required?
The FDA approved a third dosage of an mRNA vaccine (Pfizer/BioNTech or Moderna) for select immunocompromised persons in August 2021. At least 28 days following the second dose, the third dose should be given.
COVID-19 vaccines function by encouraging a person's immune system to develop antibodies against the virus, similar to other vaccines. If the antibodies come across the virus later, they will be able to recognize and eliminate it.
A person with a weaker immune system may be unable to mount a strong enough immunological response to the conventional COVID mRNA vaccine regimen, which consists of two doses.
If they do become infected, they are more likely to have a breakthrough infection, which increases the risk of more severe disease. In some immunocompromised persons, a third vaccine dosage may boost their immunological response.
For those who are moderate to severely immunocompromised, the FDA has approved the third dose. A person's immune system might be impaired for a variety of causes. Being born with immunodeficiency, having advanced or untreated HIV, and having a chronic medical condition like chronic renal disease or a spleen deficit are all examples. Many medications, including cancer therapies, TNF blockers, and biologic medicines, decrease the immune response.
What is the link between Guillain-Barré syndrome and the Johnson & Johnson COVID-19 vaccine?
The FDA issued a warning in July 2021 that the Johnson & Johnson (J&J) COVID-19 vaccine could raise the risk of Guillain-Barré syndrome by a modest but significant amount (GBS). GBS is a condition in which the body attacks and kills its nerve cells. It can cause muscle weakness and occasionally paralysis, as well as respiratory problems and, in rare cases, death. The chance of getting GBS after getting the J&J vaccine is extremely low, and the advantages of vaccination much exceed the dangers.
The FDA issued the warning after receiving preliminary reports of around 100 instances of GBS in persons who had received the J&J vaccination. Approximately 12.8 miles have been completed to date.
Almost all of them required hospitalization because GBS affects the nerves that control the chest muscles and the diaphragm, making breathing difficult. The majority of people recover fully from GBS within a few months, while some never fully recover.
Also read Coronavirus: Typical COVID symptoms that become less common following vaccination. Have you developed a new infection? Examine your signs and symptoms.
If you develop any of the following symptoms after getting the J&J COVID-19 vaccination, seek medical help right away:
trouble walking difficulties with facial movement, including speaking, chewing, or swallowing double vision or inability to move eyes difficulty with bladder control or bowel function
Comments
Write your first comment.